Navigation Links
Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
Date:3/14/2013

BRIDGEWATER, N.J., March 14, 2013 /PRNewswire/ -- If you or your loved one is at risk for anaphylaxis – a severe, life-threatening allergic reaction – you probably know the feeling of gratitude you have when someone goes the extra mile to help with allergen avoidance. Now, there is a new way to say "Thank You" to someone who has made a difference in the life of an individual at risk for anaphylaxis. Sanofi US has launched a Severe Allergy Awareness Facebook page where individuals have a unique opportunity to create online awards via the "Celebrate Someone" app for those who have helped them or a loved one manage their severe allergies. For example, an award can celebrate a co-worker who provided an allergy-friendly food option during a meeting, or a mom who substituted mylar balloons for latex balloons at a birthday party.  

Awards can recognize individuals, groups, companies or organizations, and for the first award someone makes, Sanofi US will donate $5 to a patient advocacy group focused on severe allergies – up to $100,000 in total. The donations will benefit Food Allergy Research & Education (FARE), Kids with Food Allergies Foundation (KFA) and the Asthma and Allergy Foundation of America (AAFA).

"This initiative not only raises understanding of severe allergies and the risk for anaphylaxis, but it's also a way for us to help several of the advocacy groups continue the work that they do to provide allergy education and awareness," said Bryan Downey , Vice President, Anaphylaxis Solutions, Sanofi US. "We encourage everyone who appreciates the support they've received for themselves or a family member to show their appreciation and nominate someone for the Severe Allergy Awareness Hall of Fame."  

Up to six million Americans may be at risk for anaphylaxis, although the precise incidence is unknown and likely underreported. Numerous studies indicate that the rate of anaphylaxis has increased in recent years, pointing to the need for greater awareness.

It is critical that not only the individuals at risk for anaphylaxis and their immediate family members are aware of their allergens and how to help prevent severe allergic reactions, but that others in their community are as well, including teachers, friends, coaches and co-workers.

"As a physician and someone at risk for anaphylaxis myself, I can tell you first-hand how reassuring others' awareness about my severe allergies can be," said Dr. Vivian Hernandez-Trujillo , a pediatric allergist, national expert in anaphylaxis and consultant to Sanofi US. "There are a number of people in my life who work to help ensure that I'm safe from my allergens and I look forward to recognizing them."

"Like" us today at www.facebook.com/severeallergyawareness and visit the "Celebrate Someone" app to create an award.  

About Anaphylaxis

Anaphylaxis (pronounced ana-fuh-lax-is) is a severe, life-threatening allergic reaction that happens quickly and may cause death. Life-threatening allergic reactions may occur as a result of exposure to allergens including foods such as peanuts, tree nuts, fish, shellfish, dairy, eggs, soy and wheat; insect stings; latex and medication, among other allergens and causes. Food is the most commonly identified anaphylaxis trigger and accounts for 30 percent of all anaphylaxis fatalities.

The signs and symptoms of anaphylaxis can vary from person to person and from one episode to the next. Some people may have hives/itching, facial or tongue swelling, which makes it difficult to breath or swallow, while others may experience nausea and vomiting. These symptoms may begin within seconds, minutes or hours after exposure to the allergen. The best prevention method of anaphylaxis is avoidance of the specific allergen(s). If anaphylaxis does occur and if treatment is not administered, the reaction can result in death within a matter of minutes.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.


'/>"/>
SOURCE Sanofi US
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
2. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
3. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
4. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
5. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
6. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
7. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
8. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
9. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
10. Sanofi Pasteur to add 2D barcode to six more vaccines
11. Sanofi US Launches Collaborate Activate Innovation Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
Breaking Medicine Technology:
(Date:12/9/2016)... Woodland Hills, CA (PRWEB) , ... December 09, ... ... center for young adults, celebrated its 10th anniversary with the grand opening of ... Hills, California. The successful event spanned two days, December 2-3, and was attended ...
(Date:12/9/2016)... ... December 09, 2016 , ... Mediaplanet today announces distribution of the latest ... readers to sign up as an organ donor for the 123,000 people in the ... organ donor can save up to 8 saves through organ donation and enhance many ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... program through the Pennsylvania Cable Network (PCN) during the summer of 2016. The ... Implementation Grant provided by the United States Department of Health and Human Services ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital Tampa ... Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies ... few hospitals and facilities have earned this distinction. This is the second time ...
Breaking Medicine News(10 mins):